Documents

Displaying 1 - 20 of 80 results
 
Collapse Filters
 
Expand Filters         +
October 11, 2019

Vaping and Marijuana Concentrates: What is Vaping?

Vaping is the act of inhaling and exhaling an aerosol or vapor made from a liquid or dry material that is heated in an electronic powered device, called an electronic cigarette, or e-cigarette.  In addition to nicotine and flavored liquids, marijuana concentrates can also be vaped. This 6-panel, double-sided trifold brochure covers the effects of using e-cigarettes, as well as the effects of marijuana concentrate

September 19, 2019

Drug Caused Deaths in the LA Field Division

The phenomenon of drug overdose death has grown steadily worse in the United States during most of the 21st century and has been skyrocketing since 2013 and the introduction of illicitly manufactured fentanyl-related substances into the domestic drug market...

September 16, 2019

Drug-Related Overdose Deaths in Pennsylvania, 2018 (BUL-132-19)

Since 2014, the Drug Enforcement Administration (DEA) Philadelphia Division Intelligence Program (PDIP) has annually collected and analyzed data and disseminated perceived trends and key findings that concern drug-related overdose deaths in Pennsylvania. This analysis has informed a multi-disciplinary audience relating to the drugs, populations, and geographic areas of greatest concern...

May 31, 2019

Updating the Prescription Opioid Threat in Pennsylvania

The Drug Enforcement Administration (DEA) Philadelphia Division’s Intelligence Program (PDIP) reviewed a set of data indicators for the years 2015-2018 to assess the current prescription opioid threat in Pennsylvania. Analysis revealed that a positive change in the prescription opioid threat may be underway...

April 25, 2019

SFL8 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Southwest Laboratory (SFL8).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL7 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Western Laboratory (SFL7).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL6 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the South Central Laboratory (SFL6).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL5 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the North Central Laboratory (SFL5).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL4 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Southeast Laboratory (SFL4).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL3 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Mid-Atlantic Laboratory (SFL3).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

April 25, 2019

SFL2 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Northeast Laboratory (SFL2).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

 

April 25, 2019

SFL1 Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated qualitative and quantitative methods from the Special Testing and Research Laboratory (SFL1).  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

 

April 25, 2019

Summary of Validated Methods

This document is an internal Drug Enforcement Administration quality system document which provides a summary of validated quantitative methods.  The document is updated periodically and current as of April 25, 2019 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

February 19, 2019

Athletes and Opioids Poster

What is prescription pain reliever misuse? As defined by the National Survey on Drug Use and Health, it’s “use without a prescription of one’s own or use at a higher dosage or more often than prescribed.” Prescription opioid addiction – stemming from misuse – has hit the nation hard in recent years. Unfortunately, high school student-athletes can be especially vulnerable to prescription painkiller misuse. This poster encourages teens, parents and other caregivers, and educators to know the risks around misusing pain pills.

October 29, 2018

Heroin Domestic Monitor Report

The DEA Heroin Domestic Monitor Program (HDMP) is a retail-level heroin purchase program that provides data analysis about the geographic source of heroin along with price, purity, adulterants, and diluents sold at the street-level in 27 U.S. cities. The data in this report is from 2016.

October 18, 2018

Prescription For Disaster

Increasing numbers of teens are using prescription and over-the-counter medications to get high. Many parents and caregivers don’t know enough about this problem, and many teens don’t understand the dangers. Prescription for Disaster: How Teens Abuse Medicine is a guide that helps parents and caregivers understand and identify the medications teens are abusing. An invaluable resource for parents and caregivers, Prescription for Disaster: How Teens Abuse Medicine presents prescription drug basics, includes information about commonly abused prescription drugs, lists steps parents and caregivers can take to keep their teens drug free, and more.

October 15, 2018

Opioid Threat in Pennsylvania

Crafting initiatives and strategies to address opioid supply, demand, and misuse requires timely and actionable information and data, which this report endeavors to provide. This report presents a comprehensive assessment of the opioid crisis in Pennsylvania, through collection and analysis of supply and demand indicators and intelligence, as well as detailed county level analysis of multiple opioid misuse data sources.

October 15, 2018

Heroin Signature Report

The Drug Enforcement Administration’s Heroin Signature Program (HSP) analyzed several hundred wholesale-level heroin samples in 2016 to identify the geographic area where the samples were manufactured (Mexico, South America [SA], Southwest Asia [SWA], or Southeast Asia [SEA]).

October 15, 2018

Greater New Orleans Situational Drug Report

The purpose of the Greater New Orleans Situational Drug Report is to identify current and emerging drug trends within the New Orleans metropolitan area as well as to deliver accurate and timely strategic intelligence to assist drug treatment and prevention organizations in the development of drug prevention and mitigation strategies. This assessment provides an overview of the region’s primary drug threats.

DEA US Badge
United States Drug Enforcement Administration DEA.gov is an official site of the U.S. Department of Justice